Solid Biosciences to Participate at Upcoming Investor Conferences

9/4/24 8:00:00 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $SLDB alert in real time by email

CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:

H.C. Wainwright 26^th Annual Global investment Conference – New York, NY

Bo Cumbo, President and CEO, will participate in a fireside chat on Tuesday, September 10, 2024, at 9:30 am ET.

Baird 2024 Global Healthcare Conference – New York, NY

Mr. Cumbo will present on Wednesday, September 11, 2024, at 12:50 pm ET.

A live webcast of the H.C. Wainwright fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.

Institutional investors interested in meeting with management during the conferences may reach out to their H.C. Wainwright or Baird representatives.

About Solid Biosciences

Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid's mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:

Nicole Anderson

Director, Investor Relations and Corporate Communications

Solid Biosciences Inc.

[email protected]

Media Contact:

Glenn Silver

FINN Partners

[email protected]

Get the next $SLDB alert in real time by email

Recent Analyst Ratings for

$SLDB

Date	Price Target	Rating	Analyst
7/15/2024	$10.00 → $15.00	Neutral → Overweight	JP Morgan
6/24/2024	$12.00	Market Perform → Outperform	Leerink Partners
5/31/2024	$20.00	Overweight	Piper Sandler
3/28/2024	$40.00	Outperform	William Blair
3/15/2024	$16.00	Buy	Citigroup
3/14/2024	$8.00 → $20.00	Neutral → Overweight	Piper Sandler
12/8/2023	$9.00	Buy	H.C. Wainwright
9/24/2021	$20.00 → $17.00	Buy	Chardan Capital

More analyst ratings

Solid Biosciences to Participate at Upcoming Investor Conferences

Chat with this insight

Recent Analyst Ratings for $SLDB

$SLDB Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Kahn Clare bought $8,442 worth of shares (1,100 units at $7.67) (SEC Form 4)

Perceptive Advisors Llc bought $18,861,243 worth of shares (3,410,713 units at $5.53) (SEC Form 4)

Ra Capital Management, L.P. bought $5,000,005 worth of shares (904,160 units at $5.53) (SEC Form 4)

$SLDB SEC Filings

$SLDB Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 10-Q filed by Solid Biosciences Inc.

SEC Form 10-Q filed by Solid Biosciences Inc.

SEC Form 8-K filed by Solid Biosciences Inc.

SEC Form 4 filed by Director Stone Adam Leo

SEC Form 4 filed by Director Perceptive Advisors Llc

Chief Medical Officer Brooks Gabriel converted options into 9,750 shares and sold $19,000 worth of shares (2,923 units at $6.50), increasing direct ownership by 164% to 10,979 units (SEC Form 4)

$SLDB Press Releases

Fastest customizable press release news feed in the world

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$SLDB Financials

Live finance-specific insights

Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results

Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement

Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy

$SLDB Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Solid Biosciences upgraded by JP Morgan with a new price target

Solid Biosciences upgraded by Leerink Partners with a new price target

Piper Sandler resumed coverage on Solid Biosciences with a new price target

$SLDB Market Insights

Live Market Insights

Solid Biosciences shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $10 to $15.

JP Morgan Upgrades Solid Biosciences to Overweight, Raises Price Target to $15

Solid Biosciences Joins Russell 3000 Index

$SLDB Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Solid Biosciences Inc.

SEC Form SC 13G filed by Solid Biosciences Inc.

Amendment: SEC Form SC 13G/A filed by Solid Biosciences Inc.

$SLDB Leadership Updates

Live Leadership Updates

Solid Biosciences Provides Third Quarter Business Update and Financial Results

Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer

Stoke Therapeutics Appoints Ian Smith to its Board of Directors

Recent Analyst Ratings for
$SLDB

$SLDB
Insider Purchases

$SLDB
SEC Filings

$SLDB
Insider Trading

$SLDB
Press Releases

$SLDB
Financials

$SLDB
Analyst Ratings

$SLDB
Market Insights

$SLDB
Large Ownership Changes

$SLDB
Leadership Updates